Metabolic syndrome, its pathophysiology and the role of melatonin

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 7, Issue 1, 2013, Pages 11-25

  Srinivasan, Venkataramanujam ^a   Ohta, Yoshiji ^b   Espino, Javier ^c   Pariente, José A ^c   Rodríguez, Ana B ^c   Mohamed, Mahaneem ^d   Zakaria, Rahimah ^d  

^a Sri Sathya Sai Medical Educational and Research Foundation   (India)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Diabetes; Hypertension; Insulin resistance; Melatonin; Metabolic syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; COMPLEMENT FACTOR D; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 12; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAMELTEON; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; BIOSYNTHESIS; CIRCADIAN RHYTHM; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HYDROXYLATION; HYPERGLYCEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPRACHIASMATIC NUCLEUS; THROMBOCYTE AGGREGATION; UPREGULATION; UREMIA;

EID: 84873106487     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221413804660953     Document Type: Article

References (180)

1. Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J Assoc Physicians India 2006; 54: 797-810.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
3. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Ston NR, et al. The metabolic syndrome. Endocr Rev 2008; 29: 777-822.
4. Al Saraj F, McDermott JH, Cawood T, McAteer S, Ali M, Tormey W, et al. Prevalence of the metabolic syndrome in patients of diabetes mellitus. Ir J Med Sci 2009; 178(3): 309-13.
5. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vas Biol 2008; 28: 629-36.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination survey. JAMA 2002; 287(3): 356-9.
7. Fezeu L, Balkau B, Kengne AP, Sobyngwi E, Mbanya JC. Metabolic syndrome in a sub-Saharan African setting: Central obesity may be the key determinant. Atherosclerosis 2007; 193(1): 70-6.
8. Ahonen T, Saltevo J, Laakso M, Kautiainen H, Kumpusalo E, Vanhala M. Gender differences relating to metabolic syndrome and proinflammation in Finnish subjects with elevated blood pressure. Mediators Inflamm 2009; 2009: Article ID 959281.
9. He Y, Jiang B, Wang J. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol 2006; 47: 1588-94.
10. Ogbera AO. Prevalence and gender distribution of the metabolic syndrome. Diabetol Metab Syndr 2010; 2: 1. (http://www.dmsjournal.com/content/2/1/1).
11. Ravikiran M, Bhansali A, Ravikumar P, Bhansali S, Dutta P, Thakur JS, et al. Prevalence and risk factors of Metabolic syndrome among Asian Indians: A community survey. Diabetes Res Clin Pract 2010; 89(2): 181-9.
12. Zuo H, Shi Z, Hu X, Wu M, Guo Z, Hussain A. Prevalence of the metabolic syndrome and factors associated with its components in Chinese adults. Metabolism 2009; 58(8): 1102-8.
13. Tan BY, Kantilal HK, Singh R. Prevalence of the metabolic syndrome among Malaysians using International Diabetes Federation, National Cholesterol Education Program and Modified World Health Organisation Definitions. Malays J Nutr 2008; 14(1): 65-77.
14. Ruwaida L, Zainuddin M, Isa M, Wan Muda WM, Mohamed HJ. The prevalence of metabolic syndrome according to various definitions and hypertriglyceridemic waist in Malaysian Adults. Int J Prev Med 2011; 2(4): 229-37.
15. Mohamud WN, Ismail AA, Sharifuddin A, Ismail IS, Musa KI, Kadir KA, et al. Prevalence of the metabolic syndrome and its risk factors in adult Malaysians: Results of a nationwide survey. Diabetes Res Clin Pract 2011; 91(2): 239-45.
16. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATP III, and IDF definitions in Asian Indians: The Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev 2007; 23(2): 127-34.
17. Zainuddin LR, Isa N, Muda WM, Mohamed HJ. The prevalence of metabolic syndrome according to various definitions and hypertriceridemic-waist in Malaysian adults. Int J Prev Med 2011; 2(4): 229-37.
18. Termizy HM, Mafauzy M. Metabolic syndrome and its characteristics among obese patients attending obesity clinic. Singapore Med J 2009; 50(4): 390-4.
19. Tan AK, Dunn RA, Yen ST. Ethnic disparities in metabolic syndrome in Malaysia: An analysis by risk factors. Metab Syndr Relat Disord 2011; 9(6): 441-51.
20. Narayanan P, Meng OL, Mahanim O. Do the prevalence and compounds of syndrome differ among different ethnic groups? A cross-sectional study among obese Malaysian adolescents. Metab Syndr Relat Disord 2011; 9(5): 389-95.
21. La Guardia HA, Hamm LL, Chen J. The metabolic syndrome and risk of chronic kidney disease: Pathophysiology and intervention strategies. J Nutr Metab 2012; doi: 10.1155/2012/652608.
22. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156(11): 1070-1077.
23. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total cardiovascular disease mortality in middle aged men. JAMA 2002; 288(21): 2709-16.
24. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26(3): 575-81.
25. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and the incidence of cardio vascular disease in non-diabetic subjects-a population based study comparing three different definitions. Diabetic Med 2007; 24(5): 464-72.
26. Tong PCY, Kong AP, So WY, Yong X, Ho CS, Ma RC, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007; 30(5): 1206-11.
27. Choi KM, Kim SM, Kim YE, Choi DS, Baik SH, Lee J. International diabetes federation: Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Educational Program and International Diabetes Federation definitions in the Korean population. Metab Clin Exptl 2007; 56(4): 552-8.
28. Leroith D. Pathophysiology of metabolic syndrome: Implications for the cardiometric risks associated with type 2 diabetes. Am J Med Sci 2012; 343(1): 13-6.
29. Nystrom FH, Quon M. Insulin signalling: Metabolic pathways and mechanisms for specifity. Cell Signal 1999; 11(8): 563-74.
30. Muniyappa R, Montagnani M, Koh K, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007; 28(5): 463-91.
31. Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endo Metab Clin North Amer 2008; 37(3): 685-711.
32. Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J. Dual endothelial receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary heart disease. Diabetes Care 2007; 30(3): 591-6.
33. Paz K, Hemi R, LeRoith R, Karasik A, Elhanany E, Kanety H, et al. A molecular basis for insulin resistance: Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxta-glomerulus region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997; 72: 29911-8.
34. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma adiponectin. Circulation 1999; 100(25): 2473-6.
35. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose specific protein, adiponectin, in obesity. Biochem Biophys Research Commun 1999; 257(1): 79-83.
36. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel adipose-specific protein adiponectin in type 2 diabetic patients. Arterioscler Thomb Vasc Biol 2000; 20(6): 1595-9.
37. Shimda K, Miyazaki T, Daida H. Adiponectin, and atherosclerotic disease. Clin Chem Acta 2004; 344(1-2): 1-12.
38. Nawrocki AR, Scherer PE. The delicate balance between fat and muscle: Adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharmacol 2004; 4(3): 281-9.
39. Lee EB, Warmann G, Dhir R, Ahima RS. Metabolic dysfunction associated with adiponectin deficiency enhances kainic-acid - induced seizure severity. J Neurosci 2011; 31: 14361-2.
40. Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity, and cardiovascular risk. Curr Med Chem 2010; 17: 4511-20.
41. Cui J, Panse S, Falkner B. The role of adinopectin in metabolic and vascular disease: A review. Clin Nephrol 2011; 75: 26-33.
42. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6): 2548-56.
43. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316: 129-39.
44. Wellen KE, Hotamisligil GS. Obesity induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112(12): 1785-8.
45. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across mechanisms of physiological cross-talk by adipose tissue. Am J Physiol Endocrinol Metab 2009; 296: E1210-29.
46. Tesauro M, Canale MP, Rodia G, Di Daniele N, Lauro D, Scuteri A, et al. Metabolic syndrome, chronic kidney, and cardiovascular diseases: Role of adipokines. Cardiol Res Pract 2011; 2011: Article ID 653182.
47. Tesauro M, Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiol 2011; 203: 279-86.
48. Palios J, Kadoglou NPE, Lampropoulos S. The pathophysiology of HIV/HAART-related metabolic syndrome leading to cardiovascular disorders: The emerging role of adipokines. Exptl Diabetes Res 2012; doi: 10:1155/2012/103063.
49. Smith CC, Yellon DM. Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 2011; 129: 206-19.
50. Bobbert P, Jenke A, Bobbert T, Kuhl U, Lassner D, Scheibenbogen C, et al. High leptin and resisten expression in chronic heart failure: Adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail 2012: [epub ahead of schedule].
51. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-6.
52. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Science 1996; 271: 665-8.
53. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokine: Molecular links between obesity and atherosclerosis. Am J Physiol Heart Care 2005; 288: H2031-41.
54. Bredt DS, Snyder SH. Nitric oxide: A physiologic messenger molecule. Ann Rev Biochem 1994; 63: 175-95.
55. Huang PL. Unraveling the links between diabetes, obesity, and cardiovascular disease. Cir Res 2005; 96: 1129-31.
56. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004; 53: 2060-6.
57. Eringa EC, Stehouwer CD, van Niew Amerongen GP, Ouwhand L, Westerhof N, Siokema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am J Physiol Heart Care Circ Physiol 2004; 287: H2043-8.
58. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 2007; 56: 728-34.
59. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor down regulates an endothelial nitric oxide synthase mRNA by shortening its half life. Circ Res 1993; 73: 205-9.
60. Mohamed F, Monge JC, Gordon A, Cernacek P, Blais D, Stewart DJ. Lack of role for nitric oxide (NO) in the selective destabilization of endothelial NO synthase mRNA by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 1995; 15: 52-7.
61. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumor Necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 1998; 329: 653-7.
62. Tesauro M, Schinzari F, Rovella V, Melina D, Mores N, Barini A, et al. Tumor necrosis factor-alpha antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes Care 2008; 31: 1439-41.
63. Schinzari F, Tesauro M, Rovella V, Galli A, Mores N, Porzio O, et al. Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 299: 947-52.
64. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-81.
65. Ren J. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinol 2004; 181(1): 1-10.
66. Konstantinidis S, Schafer K, Koschnick S, Loskutoff DJ. Leptindependent platelet aggregation and arterial thrombosis suggests a mechanism for athero-thrombotic disease in obesity. J Clin Invest 2001; 108(10): 1533-40.
67. Corsonello A, Perticone F, Malara A, De Domineco D, Loddo S, Buemi M, et al. Leptin dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obesity 2003; 27(5): 566-73.
68. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates pro-inflammatory immune responses. FASEB J 1998; 12(1): 57-65.
69. Parhami E, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells artery wall as a target organ. Cir Res 2001; 88(9): 954-60.
70. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth hormone releasing acylated peptide from the stomach. Nature 1999; 402(6762): 656-60.
71. Iantorno M, Chen H, Kim JA, Tesauro M, Lauro D, Cardillo C, et al. Ghrelin has novel vascular action that mimics PI3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol 2007; 292(3): E756-64.
72. Tesauro M, Schnzari F, Iantorno M, Rizza S, Melina D, Lauro D, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112(19): 2986-92.
73. Tesauro M, Iantorno M, Schinzari F, Cardillo C. Vascular effects of insulin and their relation to endothelial dysfunction, insulin resistance and hypertension. Curr Hyper Rev 2009; 5(4): 251-61.
74. Krauss RM. Dense low density lipoproteins and coronary heart disease. Am J Cardiol 1995; 75(6): 53B-57B.
75. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81(4): 13B-17B.
76. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effect of insulinresistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-62.
77. Vakkilainen J, Steiner G, Anaquer JC, Aubin F, Rattier S, Foucher C, et al. Relationship between low-density lipoprotein particle size plasma lipoproteins and progression of coronary artery disease: The Diabetes Atherosclerosis Intervention Study. Circulation 2003; 107: 1733-7.
78. Ginsberg HN. New perspectives on atherogenesis: Role of abnormal triglyceride rich lipoprotein metabolism. Circulation 2002; 106: 2137-42.
79. Spratt KA. Managing diabetic dyslipidemia: Aggressive approach. J Am Osteopath Assoc 2009; 109(5): 52-7.
80. Hardeland R, Fuhrberg B. Ubiquitous melatonin. Presence and effects in unicells, plants, and animals. Trends Comp Biochem Physiol 1996; 2: 25-45.
81. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med 2005; 9: 11-24.
82. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin - A pleiotropic, orchestering regulator molecule. Prog Neurobiol 2011; 93: 350-84.
83. Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile signal? FEBS J 2006; 273: 2813-38.
84. Bubenik GA. Gastrointestinal melatonin: Localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-48.
85. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004; 25: 177-95.
86. Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, et al. A novel melatonin metabolite, cyclic 3-hydroxyl-melatonin: A biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 1998; 253: 614-20.
87. Hirata Y, Hayaishi O, Tokuyama T, Seno S. In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 1974; 249: 1311-3.
88. Kelly RW, Amato F, Seamark RF. N-Acetyl-5-methoxy-kynurenamine, a brain metabolite of melatonin is a potent inhibitor of prostaglandin biosynthesis. Biochem Biophys Res Commun 1984; 121: 372-9.
89. Moore RY, Klein DC. Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity. Brain Res 1974; 71: 17-33.
90. Bartness TJ, Demas GE, Song CK. Seasonal changes in adiposity: The roles of the photoperiod, melatonin, and other hormones, and sympathetic nervous system. Exp Biol Med (Maywood) 2002; 227: 363-76.
91. Muhlbauer E, Peschke E. Evidence for the expression of both MT1-and in addition, the MT2-melatonin receptor, in the rat pancreas, islet, and -cell. J Pineal Res 2007; 42: 105-6.
92. Ramarcheya RD, Muller DS, Squires PE, Brereton H, Sugden D, Huang GC, et al. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res 2008; 44: 273-9.
93. Mulder H, Nagrony CL, Lyssenko V, Groop L. Melatonin receptors in pancreatic islets: Good morning to novel type 2 diabetes gene. Diabetologia 2009; 52: 1240-9.
94. Savaskan E, Olivieri G, Brydon L, Jockers R, Krauchi K, Wirz-Justice A, et al. Cerebrovascular melatonin MT1 receptor alterations in patients with Alzheimer's disease. Neurosci Lett 2001; 308: 9-12.
95. Ekmekcioglu C, Haslmayer P, Phillip C, Mehrabi MR, Glogar HD, Grimm M, et al. 24-h variations in the expression of the mt1 melatonin receptor subtype in coronary heart disease. Chronobiol Int 2001; 18: 973-85.
96. Ekmekcioglu C, Thahammer T, Humpeler S, Mehrabi MR, Glogar HD, Holzenbein T, et al. The melatonin receptor subtype MT2 is present in the cardio-vascular system. J Pineal Res 2003; 35: 40-4.
97. Brydon L, Petit L, Delagrange P, Strosberg AD, Jockers R. Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology 2001; 142: 4264-71.
98. Ekmekcioglu C. Melatonin receptors in humans, biological role and clinical relevance. Biomed Pharmacother 2006; 60: 97-108.
99. Kitagawa A, Ohta Y, Ohashi K. Melatonin improves metabolic syndrome induced by high fructose intake in rats. J Pineal Res 2012; 52(4): 403-13.
100. Espino J, Pariente JA, Rodriguez AB. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes 2011; 2(6): 82-91.
101. Achike FI, To NH, Wang H, Kwan CY. Obesity, metabolic syndrome, adipocytes, and vascular function: A holistic viewpoint. Clin Exp Pharmacol Physiol 2011; 38(1): 1-10.
102. Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci 2012; 69(5): 741-762.
103. Kozirog M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011; 50: 261-6.
104. Alemany M. Do the interactions between glucocorticoids and sex hormones regulate the development of the metabolic syndrome? Front Endocrinol (Lausanne) 2012; 3: 27.
105. Mäntele S, Otway DT, Middleton B, Bretschneider S, Wright J, Robertson MD, et al. Daily rhythms of plasma melatonin, but not plasma leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men. PLoS ONE 2012; 7(5): e37123.
106. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: A tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf) 2012; 205(2): 209-23.
107. Cardinali DP, Cano P, Ortega J, Esquifino AI. Melatonin and the metabolic syndrome: Physiopathological and therapeutical implications. Neuroendocrinology 2011; 93(3): 133-42.
108. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i xii, 1-253.
109. Vazzana N, Santilli F, Sestilli S, Cuccurullo C, Davis G. Determinants of increased cardiovascular disease in obesity and metabolic syndrome. Curr Med Chem 2011; 18(34): 5267-80.
110. Tan DX, Manchester LC, Fuentes-Broto L, Paredes SD, Reiter RJ. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: Relation to human obesity. Obesity 2010; 12: 167-88.
111. Cinti S. The role of brown adipose tissue in human obesity. Nutr Metab Cardiovas Dis 2006; 16: 569-74.
112. Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 1999; 140; 1009-12.
113. Wolden-Hanson T, Mitton DR, McCants RI, Yellon SM, Wilkinson CW, Matsumoto AM, et al. Daily melatonin administration to middle aged male rats suppresses body weight, intra abdominal adiposity, and plasma leptin, and insulin independent of food intake and total body fat. Endocrinology 2000; 141: 487-97.
114. Bojkova B, Markova M, Ahlersova E, Ahlers L, Adamekowa E, Kubatka P, et al. Metabolic effects of prolonged melatonin administration and short-term fasting in laboratory rats. Acta Vet Brno 2006; 75: 7521-32.
115. Kassayova M, Markova M, Bojkova B, Adamekova E, Kubartka P, Ahlersova E, et al. Influence of long-term melatonin administration on basic physiological and metabolic variables of young Wistar Han rats. Biologia 2006; 61: 313-20.
116. Prunet-Marcassus B, Desbazeille M, Bros A, Louche K, Delagrange P, Renard P, et al. Melatonin reduces body weight in Sprague-Dawley rats with diet induced obesity. Endocrinology 2003; 144: 5347-5352.
117. She M, Deng X, Guo Z, Laudon M, Hu Z, Liao D, et al. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol Res 2009; 59: 248-53.
118. Rios-Lugo MJ, Cano P, Jiménez-Ortega V, Fernández-Mateos MP, Scacchi PA, Cardinalli DP, et al. Melatonin effects on adinopectin leptin, insulin, glucose, triglycerides, and cholesterol in normal and high fed rats. J Pineal Res 2010; 49: 342-8.
119. Hussain MR, Ahmed OG, Hassan AF, Ahmed MA. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: An animal model. Int J Exp Pathol 2007; 88: 19-29.
120. Whaley-Connell A, McCullough PA, Sowers JR. The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med 2011; 12(1): 21-9.
121. Whaley-Connell A, Sowers JA. Oxidative stress in the cardiorenal metabolic syndrome. Curr Hyperten Rep 2012; doi: 10.1007/s11906-012-0279-2.
122. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
123. Reiter RJ. Anti oxidant actions of melatonin. Adv Pharmacol 1997; 38: 103-17.
124. Urata Y, Honma S, Goto S, Todorski S, Lida T, Cha S, et al. Melatonin induces -glutamylcysteinesynthetase mediated by activator protein -1 in human vascular endothelial cells. Free Radical Biol Med 1999; 27: 838-47.
125. Tan DX, Reiter RJ, Chen L-D, Poeggeler B, Manchester LC, Barlow-Walden LR. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen saffrole. Carcinogenesis 1994; 15: 215-8.
126. Acuna-Castroviejo D, Escames G, Leon J, Carazo A, Khaldy H. Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 2003; 527: 549-57.
127. Acuna-Castroviejo D, Escames G, Rodriguez MI, Lopez LC. Melatonin role in mitochondrial function. Front Biosci 2007; 12: 947-63.
128. Srinivasan V. Melatonin, oxidative stress and neurodegenerative diseases. Ind J Exp Biol 2002; 40: 668-79.
129. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AJ, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005; 7: 293-318.
130. Scheer FA, Van Montfrans GA, Van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin decreases nocturnal blood pressure in male patients with essential hypertension. Hypertension 2004; 46: 192-7.
131. Oxenkrug GF, Summergrad P. Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats. Ann NY Acad Sci 2010; 1199: 114-20.
132. Peschke E, Stumpf L, Bazwinsky L, Litvak L, Dralle H, Muhlbauer E. Melatonin and type 2 diabetes-a possible link? J Pineal Res 2007; 42: 350-8.
133. Peschke E, Frese T, Chankiewitz E, Peschke D, Preiss U, Schneyer U, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res 2006; 40: 135-43.
134. Kemp DM, Ubeda M, Habener JF. Identification and functional characterization of melatonin Mel1b receptors in pancreatic -cells: Potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 2002; 191: 157-66.
135. Peschke E, Schucht H, Muhlbauer E. Long-term enteral administration of melatonin reduces expression of pineal insulin receptors in both Wistar and and type 2 diabetic Goto-Kakizaki rats. J Pineal Res 2010; 49: 373-81.
136. Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat fed insulin-resistant mice. Endocrinology 2009; 150: 5311-47.
137. Sheih JM, Wu HT, Cheng KC, Cheng JT. Melatonin ameliorates high fat diet induced diabetes and stimulates glycogen synthesis via PKCzeta-Akt-GSK-3beta pathway in hepatic cells. J Pineal Res 2009; 47(4): 339-44.
138. Nishida S, Segawa T, Murai I, Nakagawa S. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty acid compositions in type-2 diabetic rats via the restoration of delta-5-desaturase activity. J Pineal Res 2002; 32: 26-33.
139. Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, Hayashi S, et al. Rats fed fructose enriched diets have characteristics of non-alcoholic hepatic steatosis. J Nutr 2009; 139: 2067-71.
140. Contreras-Alcantara S, Baba K, Tosini G. Removal of melatonin receptor type-1 induces insulin resistance in the mouse. Obesity (Silver Spring) 2010; 18: 1861-3.
141. Zanquetta MM, Seraphim PM, Sumida DH, Cipolla-Neto J, Machado UF. Calorie restriction reduces pinealectomy induced insulin resistance by improving GLUT-4 gene expression and its translocation to the plasma membrane. J Pineal Res 2003; 35: 141-8.
142. Ghosh G, De K, Maity S, Bandyopadhyay D, Bhattacharya S, Reiter RJ, et al. Melatonin protects against oxidative damage and restores expression of GLUT-4 gene in the hyperthyroid rat heart. J Pineal Res 2007; 42: 71-82.
143. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and anti-oxidative defense status of insulin-producing cells. Diabetes 1997; 46: 1733-42.
144. Anwar MM, Meki AR. Oxidative stress in streptozotocin induced diabetic rats: Effects of garlic oil and melatonin. Comp Biochem Physiol A Mol Integr Physiol 2003; 135: 539-47.
145. Bromme HJ, Ebelt H, Peschke D, Peschke E. Alloxan acts as a prooxidant only under reducing conditions. Influence of melatonin. Cell Mol Life Sci 1999; 55: 487-93.
146. Bromme HJ, Morke W, Peschke D, Ebelt H, Peschke D. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res 2000; 29: 201-8.
147. Sailaja Devi MM, Suresh Y. Preservation of the antioxidant status in chemically induced diabetes mellitus by melatonin. J Pineal Res 2000; 29: 108-15.
148. Ebelt H, Peschke D, Bromme HJ, Peschke D. Influence of melatonin on free-radical induced changes in rat pancreatic beta-cells in vitro. J Pineal Res 2000; 28: 65-72.
149. 2as mediator for DNA fragmentation. Diabetes 1991; 40: 1141-5.
150. Aksoy N, Vural H, Sabuncu T, Aksoy S. Effects of melatonin on oxidative-anti-oxidative status of tissues in streptozotocin induced diabetic rats. Vascul Pharmacol 2002; 38: 127-30.
151. Montilla PL, Vargas JF, Túnez IF, Muñoz de Agueda MC, Valdelvira ME, Cabrera ES. Oxidative stress in diabetic rats induced by streptozotocin: Protective effects of melatonin. J Pineal Res 1998; 25: 94-100.
152. Baydas G, Cantan H, Turkogllu A. Comparitive analysis of the protective effects of melatonin and vitamin E on streptozotocin-induced diabetes mellitus. J Pineal Res 2002; 32: 225-30.
153. Abdel-Wahab MH, Abd-Allah AR. Possible protective effect of melatonin and/or desferrioxamine against streptozotocin-induced hyperglycaemia in mice. Pharmacol Res 2000; 41: 533-7.
154. Andersson AK, Sandler S. Melatonin protects against streptozotocin, but not interleukin-I beta-induced damage of rodent pancreatic beta-cells. J Pineal Res 2001; 30: 157-65.
155. Sudnikovich EJ, Maksimchik YZ, Zabrodskaya SV, Kubyshin VL, Lapshina EA, Bryszewska M, et al. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur J Pharmacol 2007; 569: 180-7.
156. Bloomgarden ZT. Diabetic neuropathy. Diabetes Care 2008; 31: 616-21.
157. Schmeichel AM, Schmeizer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003; 52: 165-71.
158. Srinivasan V, Spence DW, Pandi-Perumal SR, Brown GM, Cardinali DP. Melatonin in mitochondrial function and related disorders. Int J Alzheimer's Disease 2011; 2011; 326320.
159. Acuña-Castroviejo D, López LC, Escames G, López A, García JA, Reiter RJ. Melatonin-mitochondria interplay in health and disease. Curr Topic Med Chem 2011; 11(2): 222-40.
160. Negi G, Kumar A, Kaundal RK, Gulati A, Sharma SS. Functional and biochemical evidence indicating beneficial effect of melatonin and nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 2010; 58(3): 585-92.
161. Karlsson B, Knutsson A, Lindahl B. Is there an association between shift-work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup Environ Med 2001; 58: 747-52.
162. Green B, Takahashi JS, Bass J. The meter of metabolism. Cell 2008; 134: 728-42.
163. Srinivasan V. Melatonin, biological rhythm disorders and phototherapy. Ind J Physiol Pharmacol 1997; 41: 309-28.
164. Rutter J, Reick M, McKnight SL. Metabolism and control of circadian rhythms. Annu Rev Biochem 2002; 71: 307-31.
165. Peschke E, Peschke D. Evidence for a circadian rhythm of insulin release from perfused rat pancreatic islet cells. Diabetologia 1998; 41: 1085-92.
166. Knutson KL, Ryden AM, Mander BA, van Cauter E. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med 2006; 166: 1768-74.
167. Srivastava RK, Krishna A. Melatonin modulates glucose homeostasis during winter dormancy in a vespertilionid bat, Scotophilus healti. Comp Biochem Physiol A Mol Integr Physiol 2010; 155: 392-400.
168. Mooser, V. Metabolic syndrome genetics. US20090203012 (2009).
169. Cox, D.R., Frazer, K.A., Hinds, D.A., Hyde, C.L., Thompson, J.F. Markers of metabolic syndrome. US20090186347 (2009).
170. Hauske, J.M. Treatment of metabolic syndrome with norfluoxetine. US20080140450 (2008).
171. Prescott, M. Method of managing metabolic syndrome. US20110251659 (2011).
172. Lauft, W.W. Use of S-adenosyl-methionine, Vitamin E and Vitamin C for the treatment of oxidative liver injury and insulin resistance. US8063024 (2011).
173. Cincotta, A. Therapeutic process for the treatment of the metabolic syndrome. US20050079203 (2005) & US20120129783 (2012).
174. Milind, V. Method of treatment of insulin resistance syndrome (IRS). US200100229879 (2010).
175. Cohen, E. Pharmaceutical compositions for intranasal administration comprising melatonin receptor agonists. US20090306167 (2009).
176. Beydoun MA, Shroff MB, Chen X, Beydoun HA, Wang Y, Zonderman AB. Serum antioxidant status is associated with metabolic syndrome among US adults in recent national surveys. J Nutr 2011; 141: 903-13.
177. Reiter RJ, Tan DX, Korkmaz A, Ma S. Obesity and the metabolic syndrome: Association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med 2011; doi: 10.3109/07853890.2011.586365.
178. Corbalan-Tutau MD, Madrid JA, Nicolas F, Garaulet M. Daily profile in two circadian markers "melatonin and cortisol" and associations with metabolic syndrome. Physiol Behav 2012; doi:10.1016/j.physbeh.2012.06.005.
179. Puchalski SS, Green JN, Rasmussen DD. Melatonin effect on rat body weight regulation in response to high-fat diet at middle age. Endocrine 2003; 21(2): 163-7.
180. Hoyos M, Guerrero JM, Perez-Cano R, Olivan J, Fabiani F, Garcia-Pergañeda A, Osuna C. Serum cholesterol and lipid peroxidation are decreased by melatonin in diet-induced hypercholesterolemic rats. J Pineal Res 2000; 28(3): 150-5.